arrow
J

Jamie I. Fletcher

children's cancer institute
H指数:34
被引数:9,514

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity

PLK4抑制剂RP-1664通过双重敏感性机制在神经母细胞瘤临床前模型中显示出显著疗效

2026-06-130
OAAI
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma

在多药联合化疗中加入JNK非依赖性药物可改善复发高风险神经母细胞瘤的治疗反应

2025-11-280
PRE
Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma

第二代AURKA靶向PROTACs:神经母细胞瘤体内降解的结构优化

2025-11-010
PRE
P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma
2025-11-010
OA
High-throughput 3D engineered paediatric tumour models for precision medicine

高通量3D工程化儿科肿瘤模型用于精准医学

2025-10-010
OAAI
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis

转录共阻遏物Runx1t1对于MYCN驱动的神经母细胞瘤肿瘤发生至关重要

2024-07-111
OAAI
Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone
2023-12-010
PRE
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

原发性肿瘤细胞的高通量药物筛选确定治疗高危癌症儿童的治疗策略

2023-07-3114
OAAI
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma
2023-03-038
OAAI
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma
2022-11-1710
OA
In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer

肿瘤细胞的体外和体内药物筛选确定高危儿童癌症的新疗法

2021-12-2019
OAAI